Phoenix, AZ, and Vancouver, BC. – June 28, 2017 – Eternity Healthcare Inc. (OTC: ETAH), announces it has resolved an earlier manufacturing issue effecting 10% of its syringes (nozzles) and resulting in a failure to obtain CE certification and approval. Preliminary testing of a number of nozzles, confirmed compliance with certification standards.
“We are pleased to sort out this final hurdle and look forward to CE auditors completing the inspection process for approval,” Said Dr. Salari, President & CEO
The Lenis® Needle-Free Injection system is comprised of four major components. Currently two of the components have received CE certification and approval and now the third component shall be submitted for approval. We believe the remaining components shall get the approval soon.
Needle-Free Injection System Applications
The Needle-Free Injection system can be used for a vast variety of injectable medications, and supplements. These include injection of Insulin for diabetes, injection of vaccines such as flu vaccine and many others, injection of steroids, vitamins, human growth hormones, infertility medications, a vast number of cancer drugs, cosmetic fillers and a new version of epinephrine drugs such as, Mylan’s Epipen®.
About Eternity Healthcare
Eternity Healthcare or the “Company” (OTC: ETAH) is a medical device company with technologies known as Needle-Free Injection System (the Lenis®). Our products are targeted for use by the healthcare professionals, physicians and consumers directly. More information on Eternity Healthcare, visit the Company’s website; www.eternityhealthcare.com
Safe Harbor Statement
This release includes forward-looking statements. These statements generally can be identified by phrases such as “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
President & CEO
(604) 324 -1113